Metabolic Health India
3 articles on Metabolic Health India, written by Shotlee and medically reviewed for clinical accuracy.
MSN Labs Launches Semabest: Generic Semaglutide in India
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
5 min read
50 Brands Target India's Post-Patent Semaglutide Market
India's semaglutide market is heating up with more than 50 brands poised to launch post-patent. But experts warn of a measured rollout due to the drug's intricate manufacturing demands. Inside the scramble for affordable GLP-1 access in a diabetes hotspot.
5 min read
CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
4 min read